Molecular biology laboratories + Life science laboratories

Technologies

Funtional Technologies Fulfiling Unmet Consumer Needs

At Amaterasu, collaboration is core to our R&D philosophy. We work closely with leading academic institutions, government bodies, CROs, CMOs, and innovation incubators to accelerate breakthrough ideas and bring patient-centric technologies to market.

EPB Technology

Tailored to Deliver Excellence in Skincare

We apply our scientific expertise to deliver efficacious solutions to optimise consumer benefits. Our skincare technologies are designed to strengthen the skin barrier and provide healthy skin. We handcrafted a unique anti-friction barrier technology for skincare and called it Elastomer Potentiated Barrier (EPB) technology. Silicone elastomers and polysiloxanes are uniquely blended to form a thin barrier film on the skin that cuts friction by ~ 80% and provides day long protection to the skin. We call it SECOND SKIN.

The EPB or second skin technology is non medicated, non-allergenic with potential for application in moisturization, skin protection, scar treatment, wound care, anti-chaffing and prevention of bed sores. It can seamlessly integrate into different delivery formats and with various natural ingredients. EPB technology is protected by national and international patents.

SMEDDS

Combating Malaria with Game Changing Technology Solution

A major challenge in treatment of malaria is patient noncompliance which is attributed as one major cause for incomplete cure and resistance. We have developed an innovative delivery system of Artemisinin based anti-malarial drugs. for treatment of Malaria by a single dose therapy. Currently the available injectable therapy comprises only artemisinin as mono-therapy and hence there is an unmet need for an injectable dosage form with combination ACT as recommended by WHO.

In collaboration with ICT, we have developed a unique single dose, bio-enhanced, in-situ gelling drug delivery system for intramuscular injection for treatment of malaria. The single dose injection will bring a radical shift in treatment of malaria from 6 days treatment to a single dose injection thus enabling: